BCAX · Bicara Therapeutics Inc
United States · RS rating 14 · As of 2026-10-14
| Price | 17.34 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 9 / 8 / 36 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 16 / 14 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -1.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +43.0% |
| Market cap (USD) | $1.5B |